Is CEL-SCI Corporation (CVM) a Buy, Sell, or Hold?
CEL-SCI Corporation
AMEX:CVM
$1.15 USD
-$0.07 (-5.74%)
- Volume
- 321.73K
- Average Volume
- 506.91K
- Market Capitalization
- $7.9M
- P/E Ratio
- -0.33
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $13.48
- Year Low
- $0.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.60
| Source | Headline |
|---|---|
|
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer. businesswire.com - 2026-07-13 08:00:00 |
|
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care. businesswire.com - 2026-06-24 08:00:00 |
|
CEL-SCI Announces Closing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering. businesswire.com - 2026-06-16 16:01:00 |
|
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy. businesswire.com - 2026-06-16 08:00:00 |
|
CEL-SCI Corporation Announces Pricing of Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering. businesswire.com - 2026-06-14 19:03:00 |
|
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine. businesswire.com - 2026-06-12 08:00:00 |
|
CEL-SCI Reports Fiscal Second Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine. businesswire.com - 2026-05-18 08:00:00 |
|
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering. businesswire.com - 2026-05-13 15:00:00 |
|
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering. businesswire.com - 2026-05-11 20:11:00 |
|
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia. businesswire.com - 2026-05-11 08:00:00 |
|
Itaú Unibanco Holding files 2025 Form 20-F with the SEC and the CVM
SÃO PAULO, April 30, 2026 /PRNewswire/ -- Itaú Unibanco Holding S.A. (the "Company") announces to the market that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on April 29, 2026. prnewswire.com - 2026-04-30 08:07:00 |
|
Cel-Sci (NYSEAMERICAN:CVM) Shares Down 0.9% – What’s Next?
Cel-Sci Corporation (NYSEAMERICAN:CVM - Get Free Report) was down 0.9% on Thursday. The stock traded as low as $3.27 and last traded at $3.31. Approximately 30,767 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 62,532 shares. The stock had previously closed at $3.34. Cel-Sci Stock Down defenseworld.net - 2026-04-24 02:21:08 |
